|
1. DeGroot J. The AGE of the matrix: chemistry, consequence and cure. Curr Opin Pharmacol. 2004 Jun;4(3):301-5. Review.
2. Peppa M, Uribarri J, Vlassara H. Aging and glycoxidant stress. Hormones (Athens). 2008 Apr-Jun;7(2):123-32. Review.
3. Gasser A, Forbes JM. Advanced glycation: implications in tissue damage and disease. Protein Pept Lett. 2008;15(4):385-91.
4. Hyogo H, Yamagishi S. Advanced glycation end products (AGEs) and their involvement in liver disease. Curr Pharm Des. 2008;14(10):969-72. Review.
5. Susic D. Cross-link breakers as a new therapeutic approach to cardiovascular disease. Biochem Soc Trans. 2007 Nov;35(Pt 5):853-6. Review.
6. Gul A, Rahman MA, Salim A, et al. Advanced glycation end products in senile diabetic and nondiabetic patients with cataract. J Diabetes Complications. 2008 May 26. [Epub ahead of print]
7. Pawlak AM, Glenn JV, Beattie JR, et al. Advanced glycation as a basis for understanding retinal aging and noninvasive risk prediction. Ann N Y Acad Sci. 2008 Apr;1126:59-65.
8. Tezel G, Luo C, Yang X. Accelerated aging in glaucoma: Immunohistochemical assessment of advanced glycation end products in the human retina and optic nerve head. Invest Ophthalmol Vis Sci. 2007 Mar;48(3):1201-11.
9. Nazratun N, Mahmood AA, Kuppusamy UR, et al. Diabetes mellitus exacerbates advanced glycation end product accumulation in the veins of end-stage renal failure patients. Vasc Med. 2006 Nov;11(4):245-50.
10. Suliman ME, Stenvinkel P, Jogestrand T, et al. Plasma pentosidine and total homocysteine levels in relation to change in common carotid intima-media area in the first year of dialysis therapy. Clin Nephrol. 2006 Dec;66(6):418-25.
11. Sakata N, Imanaga Y, Meng J, et al. Increased advanced glycation end products in atherosclerotic lesions of patients with end-stage renal disease. Atherosclerosis. 1999 Jan;142(1):67-77.
12. Sell DR, Monnier VM. Conversion of arginine into ornithine by advanced glycation in senescent human collagen and lens crystallins. J Biol Chem. 2004 Dec 24;279(52):54173-84.
13. Ravelojaona V, Robert AM, Robert L. Expression of senescence-associated beta-galactosidase (SA-beta-Gal) by human skin fibroblasts, effect of advanced glycation end-products and fucose or rhamnose-rich polysaccharides. Arch Gerontol Geriatr. 2008 Jan 18.
14. Pageon H, Técher MP, Asselineau D. Reconstructed skin modified by glycation of the dermal equivalent as a model for skin aging and its potential use to evaluate anti-glycation molecules. Exp Gerontol. 2008 Jun;43(6):584-8.
15. Reddy VP, Garrett MR, Perry G, et al. Carnosine: a versatile antioxidant and antiglycating agent. Sci Aging Knowledge Environ. 2005 May 4;2005(18):pe12. Review.
16. Hammes HP, Du X, Edelstein D, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med. 2003 Mar;9(3):294-9.
17. Nagai R, Fujiwara Y, Mera K, et al. Investigation of pathways of advanced glycation end-products accumulation in macrophages. Mol Nutr Food Res. 2007 Apr;51(4):462-7.
17a. Williams ME, Bolton WK, Khalifah RG, et al. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol. 2007;27(6):605-14.
18. Padival S, Nagaraj RH. Pyridoxamine inhibits maillard reactions in diabetic rat lenses. Ophthalmic Res. 2006;38(5):294-302.
19. Waanders F, van den Berg E, Nagai R, et al. Renoprotective effects of the AGE-inhibitor pyridoxamine in experimental chronic allograft nephropathy in rats. Nephrol Dial Transplant. 2008 Feb;23(2):518-24.
20. Fujiwara Y, Kiyota N, Motomura K, et al. Some natural compounds enhance N epsilon-(carboxymethyl)lysine formation. Ann N Y Acad Sci. 2008 Apr;1126:152-4.
21. Szabó C. The pathophysiological role of peroxynitrite in shock, inflammation, and ischemia-reperfusion injury. Shock. 1996 Aug;6(2):79-88. Review.
22. Cuzzocrea S, Thiemermann C, Salvemini D. Potential therapeutic effect of antioxidant therapy in shock and inflammation. Curr Med Chem. 2004 May;11(9):1147-62. Review.
23. Vasto S, Carruba G, Lio D, et al. Inflammation, ageing and cancer. Mech Ageing Dev. 2008 Jul 10.
24. Müller-Werdan U. Inflammation and ageing. Z Gerontol Geriatr. 2007 Oct;40(5):362-5. Review.
25. Passos JF, von Zglinicki T, Kirkwood TB. Mitochondria and ageing: winning and losing in the numbers game. Bioessays. 2007 Sep;29(9):908-17.
26. Seidman MD, Khan MJ, Bai U, et al. Biologic activity of mitochondrial metabolites on aging and age-related hearing loss. Am J Otol. 2000 Mar;21(2):161-7.
27. Ames BN. Delaying the mitochondrial decay of aging. Ann N Y Acad Sci. 2004 Jun;1019:406-11.
28. Harman D. Free radical theory of aging: a consequences of mitochondrial aging. Age. 1983 6:86-94
29. Miquel J., Fleming JE. A two step hypothesis on the mechanisms of in vitro cell aging: cell differentiation followed by intrinsic mitochondrial mutagenesis. Exp Gerontol. 1984 19: 31-36
30. Shigenaga MK., Hagen TM., Ames BN., Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci USA. 1994 91:10771-10778
31. Hagen TM., Yowe DL, Bartholomew JC., et al. Mitochondrial decay in hepatocytes from old rats: membrane potential declines, heterogeneity and oxidants increase. Proc Natl Acad Sci USA. 1997 94:3064-3069
32. Beckman KB., Ames BN., Mitochondrial aging: open questions. Ann NY Acad Sci. 1998; 854:118-127
33. Maitra I, Serbinova E, Tritschler HJ, et al. Stereospecific effects of R-lipoic acid on buthionine sulfoximine-induced cataract formation in newborn rats. Biochem Biophys Res Commun. 1996 Apr 16;221(2):422-9.
34. Hagen TM, Ingersoll RT, Lykkesfeldt J, et al. (R)-alpha-lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate. FASEB J. 1999 Feb;13(2):411-8.
35. Hagen TM, Vinarsky V, Wehr CM, et al. (R)-alpha-lipoic acid reverses the age-associated increase in susceptibility of hepatocytes to tert-butylhydroperoxide both in vitro and in vivo. Antioxid Redox Signal. 2000 Fall;2(3):473-83.
36. Scorziello A, Meucci O, et al. Acetyl-L-carnitine arginine amide prevents beta 25-35-induced neurotoxicity in cerebellar granule cells. Neurochem Res. 1997 Mar;22(3):257-65.
37. Taglialatela G, Navarra D, Olivi A, et al. Neurite outgrowth in PC12 cells stimulated by acetyl-L-carnitine arginine amide. Neurochem Res. 1995 Jan;20(1):1-9.
38. Chen CY, Peng WH, Tsai KD, et al. Luteolin suppresses inflammation-associated gene expression by blocking NF-kappaB and AP-1 activation pathway in mouse alveolar macrophages. Life Sci. 2007 Nov 30;81(23-24):1602-14.
39. Harris GK, Qian Y, Leonard SS, et al. Luteolin and chrysin differentially inhibit cyclooxygenase-2 expression and scavenge reactive oxygen species but similarly inhibit prostaglandin-E2 formation in RAW 264.7 cells. J Nutr. 2006 Jun;136(6):1517-21.
40. Hougee S, Sanders A, Faber J, et al. Decreased pro-inflammatory cytokine production by LPS-stimulated PBMC upon in vitro incubation with the flavonoids apigenin, luteolin or chrysin, due to selective elimination of monocytes/macrophages. Biochem Pharmacol. 2005 Jan 15;69(2):241-8.
41. Kim JS, Jobin C. The flavonoid luteolin prevents lipopolysaccharide-induced NF-kappaB signaling and gene expression by blocking IkappaB kinase activity in intestinal epithelial cells and bone-marrow derived dendritic cells. Immunology. 2005 Jul;115(3):375-87. |